These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10212778)

  • 1. [Long-term immunological study on postoperative adjuvant treatment with interferon-gamma in patients with renal cell carcinoma who underwent nephrectomy].
    Miura H; Arai H; Matsuoka A; Yazawa K; Satoh E; Nishimura K; Honda M; Fujioka H
    Hinyokika Kiyo; 1999 Feb; 45(2):79-83. PubMed ID: 10212778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
    Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
    Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
    Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
    Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
    Onishi T; Machida T; Masuda F; Igarashi H
    Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
    Kawata N; Ono M; Endo M; Ichinose T; Hamada T; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunological study of interferon-gamma therapy for advanced renal cell carcinoma].
    Aoyagi T; Murai M; Kimura F; Sawamura M; Asano T; Odajima K; Nagakura K; Nakamura H
    Hinyokika Kiyo; 1992 Dec; 38(12):1357-60. PubMed ID: 1288223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy].
    Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome from a study on the prevention of postoperative recurrence in patients with renal cell carcinoma: could PBL be a predictor of postoperative recurrence in patients postoperatively treated with IFN-gamma?
    Kawata N; Ichinose T; Hachiya T; Hirakata H; Igarashi T; Nagane Y; Morita K; Takimoto Y
    Hinyokika Kiyo; 2006 Aug; 52(8):603-8. PubMed ID: 16972621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
    Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
    Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
    Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of lymphocytic population in peripheral blood of patients with renal cell carcinoma before and after embolization.
    Osada J; Pietruczuk M; Dabrowska M; Kordecki K; Janica J; Walecki J
    Rocz Akad Med Bialymst; 2000; 45():228-39. PubMed ID: 11712434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multidisciplinary therapy using interferon and immunological evaluation for glioma patients: two-color analysis of T cell subsets].
    Numa Y; Kawamoto K; Matsumura H
    No Shinkei Geka; 1991 Feb; 19(2):121-8. PubMed ID: 1708857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effects and immunological changes in interferon therapy for advanced renal cell carcinoma].
    Kudo T; Souma H; Kudo S; Kogawa T; Suzuki T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):40-6. PubMed ID: 2109026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-lymphocyte subsets in the peripheral blood of patients with renal cell carcinoma.
    Mitropoulos D; Alamanis C; Deliveliotis C; Zervas A; Tzirakis A; Dimopoulos C
    Acta Urol Belg; 1995 Sep; 63(3):21-5. PubMed ID: 7484518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
    Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
    Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunological effect of recombinant interferon-gamma on tumor infiltrating lymphocytes of renal cell carcinoma--relationship with clinical stage].
    Kawata N; Takimoto Y; Hirano D; Yamamoto T; Hirakata H; Yamanaka Y; Okada Y; Chino K; Sugimoto S; Igarashi T
    Hinyokika Kiyo; 1996 Jan; 42(1):1-4. PubMed ID: 8686575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.